Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response

Overview of attention for article published in Journal for Immunotherapy of Cancer, October 2019

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 40 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 8,462 followers.

#JITC Case Report: Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response https://t.co/WbJ033aBFl https://t.co/phZ9EHEZ8m

21 Nov 2019

Reply Repost Favourite

RT @jitcancer: New #JITC Case Report: Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related a…

15 Nov 2019

Reply Repost Favourite

New #JITC Case Report: Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response https://t.co/WbJ033aBFl https://t.co/ASANkHQFIM

14 Nov 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.